Antares Pharma plans to launch Tlando, which doesn’t require dose titration, in the second quarter of 2022.
Formulary Watch
Latest News
All News
Advertisement
The FDA determined that the benefits of the second booster dose outweighed the risks after reviewing data from Pfizer, BioNTech, and Moderna.
Ozempic is now available in three doses to improve blood sugar in people with type 2 diabetes.
Prior authorization and step therapy can impact compliance and outcomes, according to a survey by the Pharmaceutical Research and Manufacturers of America.
The FDA has okayed allowing patients to start treatment with the injection instead of having a lead in with the oral version.
Xipere is a targeted treatment that is delivered via an injection to the back of the eye to treat macular edema associated with uveitis, a form of eye inflammation.
Fintepla was approved to treat Lennox-Gastaut syndrome, which first appears in childhood and can affect neurodevelopmental, cognitive, and motor functions.
This real-world study found that patients who received Relistor SC during an emergency department visit for opioid induced constipation had lower costs and hospital lengths of stay.
Some generics have as much of a 10,000-times increase from the manufacturers weighted average manufacturers price to what a patient could pay at the pharmacy if they chose to pay the cash price.
Reblozyl is being reviewed to treat anemia in patients with beta thalassemia. The new date is June 27, 2022.
Advertisement
The recall was related to syringes in these lots malfunctioning.
Pluvicto is the first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer.
The FDA has asked for an additional clinical trial with overall survival as the endpoint.
The new code will be effective April 1, 2022.
The study aims to generate data related to Tremfya in people of color who have plaque psoriasis.
The recall of orphenadrine was due to the presence of the cancer-causing nitrosomine.
Cystaran is a topical ophthalmic therapy that is used to treat a rare genetic disorder.
The CRL delays the commercial return in the United States, Takeda didn’t release any information about the reason for the CRL.
The recall of Accuretic and generics distributed by Greenstone is a result of the presence of a cancer-causing agent.
The FDA also approved a companion diagnostic to select patients with mismatch repair deficiency who would be eligible for treatment with Keytruda.
But there is no significant difference in rate of hospitalization for major bleeding when Eliquis is compared with Xarelto or warfarin.
Opdualag is a first-in-class immunotherapy that combines Opdivio with the novel LAG-3-blocking antibody relatlimab.
Teplizumab is being evaluated to delay type 1 diabetes. The PDUFA date is August 17, 2022.
Ztalmy was approved for seizures associated with CDKL5 deficiency disorder in patients two years of age and older. It is expected to be available in July 2022.
Del Doherty, co-founder of Prodigy Rx, discusses how the PBM aims to give payers control so they can lower costs and can improve clinical and return-to-work outcomes.
Amneal is of 35 global companies selected to manufacture and commercialize generic version of COVID-19 treatment Paxlovid.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Arpit Patel. Pharm.D., MedImpact
2
Investigational non-opioid LTG-001 reduced acute pain in phase 2b trial
3
Ashley Holzworth-Nash, Pharm.D., Evernorth
4
CMS sets the 2027 Part D bid amount at $296.05, will end premium subsidy program
5